I-Darunavir Ethanolate CAS 635728-49-3 Purity ≥99.0% API Factory Anti-HIV HIV Protease Inhibitor
Umkhiqizi Wemikhiqizo Ehlobene ne-Darunavir:
I-Darunavir CAS 206361-99-1
I-Darunavir Ethanolate CAS 635728-49-3
(2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98737-29-2
(2R,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98760-08-8
(3S)-3-(tert-Butoxycarbonyl)amino-1-Chloro-4-Phenyl-2-Butanone CAS 102123-74-0
| Igama Lekhemikhali | I-Darunavir Ethanolate |
| Omqondofana | I-DRV;I-Prezista;I-TMC114 Ethanolate;I-UNII-33O78XF0BW;N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro [2,3-b]furan-3-yl ester compd.nge-ethanol |
| Inombolo ye-CAS | 635728-49-3 |
| Inombolo yeCAT | I-RF-API69 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
| I-Molecular Formula | I-C29H43N3O8S |
| Isisindo samangqamuzana | 593.73 |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Ukubukeka | I-Crystalline Powder Emhlophe noma Engamhlophe |
| Ukuhlonza IR | Ihambisana ne-Standard Spectrum |
| Ukuzungezisa okuqondile | -0.5°~ +0.5° |
| Izinto Ezihlobene | (nge-HPLC) |
| Ukungcola Okukodwa Okukhulu | ≤0.20% |
| Ukungcola Okuphelele | ≤0.50% |
| Amanzi (KF) | ≤1.0% |
| Izinsalela ekushiseni | ≤0.10% |
| Izinsimbi Ezisindayo | ≤10ppm |
| Okuqukethwe kwe-Ethanol | ≤7.5% (GC) |
| Izincibilikisi Ezisele | I-Methanol ≤0.30% |
| Ubumsulwa | ≥99.0% (HPLC) |
| Izinga Lokuhlola | I-Enterprise Standard |
| Ukusetshenziswa | I-Darunavir Ethanolate HIV-1 Protease Inhibitor Anti-HIV Antiviral |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, I-Cardboard Drum, 25kg/Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni, umswakama kanye nezinambuzane.
I-Darunavir Ethanolate (Prezista) iyi-HIV protease inhibitor.Okuphuma ku-Darunavir, isizukulwane sesibili se-HIV-1-protease inhibitor;ngokwesakhiwo ifana ne-amprenavir.I-Antiviral.Kungumkhiqizo wocwaningo ohlobene ne-COVID19.Ngeshwa, i-DRV inokunyibilika okuphansi emanzini kanye nokungabibikho kahle kwe-bioavailability, ngakho-ke idinga ukuphathwa ngemithamo ephezulu kakhulu ukuze kuboniswe ukusebenza ngempumelelo kokwelapha.I-Darunavir iyisivimbeli esinamandla esibanzi esisebenza ngokumelene ne-HIV-1 ihlukaniswe yomtholampilo ene-cytotoxicity encane.I-Darunavir yakha amabhondi e-hydrogen nama-athomu eketango eliyinhloko agciniwe e-Asp29 kanye ne-Asp30 ye-protease.Lokhu kusebenzisana kuhlongozwa ukuthi kubaluleke kakhulu kumandla alesi sithako esiphikisana ne-HIV isolates amelana nama-protease inhibitors amaningi.Ocwaningweni lwe-in vitro kumaseli e-MT-2, amandla e-darunavir makhulu kunalawo e-saquinavir, amprenavir, nelfinavir, indinavir, lopinavir ne-ritonavir.I-Darunavir igaywe ngokuyinhloko ama-enzyme e-hepatic cytochrome P450 (CYP), ngokuyinhloko i-CYP3A.Umthamo 'okukhuthazayo' we-ritonavir usebenza njengesivimbeli se-CYP3A, ngaleyo ndlela andisa ukutholakala kwe-darunavir bioavailability.I-Darunavir yakhelwe ukwakha ukusebenzisana okuqinile ne-protease enzyme evela ezinhlotsheni eziningi ze-HIV, okuhlanganisa nezinkinga ezivela ezigulini ezinolwazi lokwelashwa ezine-multiple resistance mutati.
